Dr. Reddy's Semaglutide Setback Weighs but Base Holds Steady

INR 240 crore provision and Middle East drag pressure Q1, but management reaffirms double-digit base growth and a November semaglutide comeback.

RDY · Earnings Call · 2026-07-22

Dr. Reddy's Laboratories faced a challenging quarter as a semaglutide API quality issue and Middle East-driven cost pressures masked an otherwise resilient base business. CFO M. V. Narasimham opened with the headline numbers: “The business reported revenue decline of 5.6% and EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding period last year, as well as a provision of INR 240 crores for inventory and other costs associated with the recent semaglutide API-related challenges.” — M. V. Narasimham, Chief Financial Officer (CFO) · 2026-07-22 The semaglutide API problem forced a provision of INR 240 crore and halted commercial supplies, but management has identified the root cause and targets a November resumption. CEO Erez Israeli noted: “We are working towards resolving the issue and are planning to resume semaglutide commercial supplies by November.” — Erez Israeli, Chief Executive Officer (CEO) · 2026-07-22 This is a company-specific event, but it comes against a backdrop of global Middle East conflict that is inflating costs across industries.

We identified the root cause. We started also the activities in the sites. There is a program management that takes us again to around September 2026. The success rate is high. I don't know the exact percentage. If I need to throw a number, it's somewhere between 80%-90%, but there is a chance that it will fail. I just want to make sure it's not 100%, but we feel relatively confident. Let's cross our fingers on that.
Erez Israeli, Chief Executive Officer (CEO) · 2026-07-22

The commercial impact of the suspended supply is significant; the company had sold only 180,000 pens before halting, and now plans to sell 6–7 million pens between November and March, backed by partner orders. While the API issue is unique to Dr. Reddy's, it sits within a broader GLP-1 wave that continues to dominate specialty pharma. The company has also expanded its India footprint, with the branded franchise (India, emerging markets, NRT) accounting for 42% of revenue. India posted 17% growth, and emerging markets 31%, driven by new product launches and favorable currency.

Base Business Resilience and Biosimilar Catalyst

Stripping out lenalidomide, the U.S. business grew double digits, driven by new complex generics like bosutinib and nintedanib. The company reaffirmed double-digit growth for the U.S. ex-lena. The biosimilar pipeline is the key swing factor, with abatacept at the center. After an FDA inspection that yielded seven observations, the company submitted a response and still sees a December goal date. "In my opinion, we should get approval," Erez Israeli stated, echoing confidence. This is a consistent narrative; back in January, the team had targeted "somewhere towards the end of the calendar of '26" for IV approval, as noted in the prior call. “The first expectation is that we'll get somewhere towards the end of the calendar of '26, the approval for the IV product and then we can launch it.” — Erez Israeli, Chief Executive Officer · 2026-01-21 The U.S. business remains the cash cow, while biosimilars are expected to become the next growth engine. On margins, management is holding the line. Excluding semaglutide, the base business should remain in the "neighborhood of 20%," a commitment that echoes the May call: “So we are planning to maintain the base without Sema at around 20%. So this is the plan.” — Erez Israeli, Chief Executive Officer · 2026-05-12 The company's cost-control measures, including productivity initiatives across sales and marketing, are designed to support margin improvement through the year. Full-year tax rate guidance is 24–25%, and R&D spend will stay at 7–8% of revenue.

Global Confluence and Strategic Direction

The pressure points at Dr. Reddy's are not isolated. Many companies across the globe are flagging tariff refunds and supply-chain dislocations. For Dr. Reddy's, the immediate concern is the Middle East conflict, which it estimates cost about 1% of EBITDA in the quarter, primarily through solvents and freight. Tariffs on generics are a watch item, but management downplayed near-term risk, noting that 25–30% of revenue is already manufactured by CMOs in the U.S. and any tariff would take years to shift production. With a net cash surplus of INR 3,057 crore and a stated capacity to deploy up to $2.5 billion in inorganic opportunities, the company has dry powder for business development. As the fiscal year unfolds, the path to margin recovery hinges on the semaglutide resumption and regulatory milestones. CEO Israeli firmly reiterated the margin commitment: “We are still, I maintain, what we discussed a few weeks ago, that we are in the neighborhood of the 20% and likely to stay, and that's what we are saying we will do in the next quarter, including the next quarter, which will not be with semaglutide.” — Erez Israeli, Chief Executive Officer (CEO) · 2026-07-22 If that holds, the base business truly is resilient, and the semaglutide setback becomes a temporary blemish rather than a structural shift.